Introduction Measurable residual disease (MRD) is one of the most important prognostic factors for progression-free and overall survival in multiple myeloma  With the recent 2024 FDA ODAC decision to accept MRD as an endpoint for clinical trials in MM, there is an increasing desire to find even more sensitive and less invasive [...]